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Background: The level of access to intermittent preventive treatment for malaria in pregnancy (IPTp) in Nigeria is
still low despite relatively high antenatal care coverage in the study area. This paper presents information on
provider factors that affect the delivery of IPTp in Nigeria.
Methods: Data were collected from heads of maternal health units of 28 public and six private health facilities
offering antenatal care (ANC) services in two districts in Enugu State, south-east Nigeria. Provider knowledge of
guidelines for IPTp was assessed with regard to four components: the drug used for IPTp, time of first dose
administration, of second dose administration, and the strategy for sulphadoxine-pyrimethamine (SP) administration
(directly observed treatment, DOT). Provider practices regarding IPTp and facility-related factors that may explain
observations such as availability of SP and water were also examined.
Results: Only five (14.7%) of all 34 providers had correct knowledge of all four recommendations for provision of
IPTp. None of them was a private provider. DOT strategy was practiced in only one and six private and public
providers respectively. Overall, 22 providers supplied women with SP in the facility and women were allowed to
take it at home. The most common reason for doing so amongst public providers was that women were required
to come for antenatal care on empty stomachs to enhance the validity of manual fundal height estimation. Two
private providers did not think it was necessary to use the DOT strategy because they assumed that women would
take their drugs at home. Availability of SP and water in the facility, and concerns about side effects were not
considered impediments to delivery of IPTp.
Conclusion: There was low level of knowledge of the guidelines for implementation of IPTp by all providers,
especially those in the private sector. This had negative effects such as non-practice of DOT strategy by most of the
providers, which can lead to low levels of adherence to IPTp and ineffectiveness of IPTp. Capacity development and
regular supportive supervisory visits by programme managers could help improve the provision of IPTp.
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Nigeria adopted the intermittent preventive treatment for
malaria in pregnancy (IPTp) strategy in 2001 [1]. Although
studies in Nigeria show the efficacy of IPTp in preventing
anaemia in pregnancy among Nigerian women [2-4], there
is still low coverage of the intervention in Nigeria. The* Correspondence: chimaonoka@yahoo.com
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reproduction in any medium, provided the ormost recent demographic and health survey (DHS) in
Nigeria revealed that both first and second dose coverage
remain low, being 8.0% and 4.6% respectively in Nigeria,
and 9.9% and 5.4% in south-east Nigeria [5]. A recent
study [6] reported values of 13.7% and 7.3% for first and
second doses, respectively.
IPTp using sulphadoxine-pyrimethamine (SP) is given
to pregnant women during antenatal care visits on at
least two occasions following quickening; a dose during
the second and during the third trimesters of pregnancy
under direct observation [7]. Antenatal care (ANC) isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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doctors or nurses, who have been educated and suffi-
ciently trained to provide care for women during preg-
nancy, delivery and the six-week period following
pregnancy [8]. Although data about the health facility
type used by women for ANC are unavailable, 25.3% and
48.6% of live birth deliveries in south-east Nigeria occur
in public and private facilities respectively, with the re-
mainder occurring mainly at home [5]. While 58% of
pregnant women in Nigeria receive ANC from a skilled
birth attendant, the figure is 87% for the south-east re-
gion of the country [5]. However, attendance at antenatal
care does not guarantee effective delivery of IPTp as
favourable provider-side factors need to be in place as
well [9].
Since antenatal clinics serve as the usual entry point
for IPTp implementation [10], the nature of service
provision in the clinics as well as attendance by pregnant
women is key to optimal IPTp coverage. Facility and
policy-related factors were reported as being more ser-
ious impediments to IPTp coverage in Tanzania than the
timing of ANC attendance [11]. The poor level of know-
ledge of guidelines for IPTp delivery amongst health
workers in Malawi negatively affected IPTp delivery [12].
Health workers have also been found to offer all women
IPTp (including first trimester clients) during their first
clinic visit [13]. In some cases, health workers are
confused about the appropriate timing of first dose, and
spacing between doses of SP, resulting in low coverage
[12]. In Malawi some health workers were of the opinion
that SP should not be taken on an empty stomach,
which reduced the delivery of SP under direct observa-
tion [12]. Unavailability of clean water in Malawi, drug
stock-outs in Kenya, Tanzania, Uganda and Zambia, and
staff shortages in antenatal clinics in Uganda have also
negatively impacted coverage levels [9].
Studies in Nigeria have reported low knowledge of IPTp
guidelines amongst a sample of all cadres of health care
providers [14], and poor experience of directly-observed
treatment (DOT) strategy among ANC attendees with
36.8% of women offered IPTp taking it in the facility and
only 14.3% doing so under health worker observation [15].
However, little is known about the knowledge and prac-
tices of the health providers who primarily play the role of
ANC providers in health facilities.
This paper provides new information about the pro-
vider factors at ANC clinic level that affect the delivery
of IPTp in Nigeria and complements the evidence gener-
ated by the demand side component of the study, which
suggested that supply rather than demand side factors
may be responsible for the low coverage of IPTp in
Nigeria [6]. The paper provides information on health
worker knowledge of IPTp policy, actual health worker
practices, the underlying reasons for such practices, andother facility requirements for IPTp delivery. Such infor-
mation is critical for understanding supply-side impedi-
ments to effectiveness of the IPTp policy and identifying




The study was conducted in Enugu North and South local
government areas (LGA) and Udi LGA in Enugu State,
south-east Nigeria, in 2010. Udi LGA (rural) has a popula-
tion of 244,852, and Enugu North and South (urban) have
a combined population of 443,575 [16]. The public health
care delivery system in the state is organized in three levels
based on a District Health System with primary level facil-
ities being the entry point for health care utilization. This
level also serves as the primary point of delivery of ANC
services. In Udi and Enugu, 17 and 11 of such public
health facilities, respectively, offer ANC services. In
addition, there are several private health facilities in Enugu
while six major ones exist in Udi. Each health facility has
an ANC/maternity unit that has responsibility for provid-
ing ANC, family planning and delivery services. An ANC/
maternity unit is headed by staff of the facility with rele-
vant skills for maternal health service delivery, and ANC
clinics are held twice a week.
Context
Malaria is highly endemic in Enugu [17]. In line with the
policy of the Federal Ministry of Health (FMOH) [1], the
state implements IPTp delivery. Implementation of IPTp
involves use of SP for IPTp, delivery of the first dose
after the 16th week of pregnancy, and provision of two
doses for pregnant women at least four weeks apart, and
three for HIV-positive pregnant women. Health workers
are not to give SP within the four-week period preceding
a woman’s expected date of delivery, quite unlike the
WHO regulation which allows IPTp to be offered at this
time [7], and it must not be offered within the first tri-
mester of pregnancy. The strategy also stipulates that
the health providers should give SP under direct obser-
vation at the health facility. Healthcare providers that
provide ANC services receive training through workshops
organized by the state Ministry of Health, and other non-
governmental organizations involved in malaria control.
These organizations also distribute posters and leaflets
that specify the guidelines for delivery of IPTp to both
public and private health care facilities [18].
Data collection
Data were collected using an in-depth interview guide
and a checklist. The interview guide was used to collect
data from the heads of the ANC/maternity units in all
the 28 public primary health facilities offering ANC
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posely selected private hospitals (three from each district).
The information obtained included health workers’ know-
ledge of the existence of a policy on IPTp, the procedures
for delivery of IPTp, as well as the reasons underlying
observed practices. In-depth interviews were recorded
using a digital voice recorder. A facility checklist was also
used to obtain information on availability of SP and water
for ANC on the day that the facility was visited. In
addition the number of ANC clients, and the skilled atten-
dants as defined by WHO [8] that ran the ANC clinics for
the week preceding the facility visit were obtained from
the facility staff register to enable determination of the
ratio of ANC client/skilled attendant per clinic day. The
number of unskilled staff (such as community health ex-
tension workers (CHEWs) who do not receive midwifery
training) providing assistance, or fully manning, a unit was
obtained.
Data analysis
Recorded interviews were transcribed following each
interview. The transcripts were coded based on prede-
termined themes corresponding to the main categories
of interest. Information given by each provider was com-
pared with the FMOH implementation guidelines for
IPTp delivery in order to determine whether the pro-
vider had correct or incorrect knowledge of any of the
components, and the number of providers that knew the
four components that served as criteria for assessment
of knowledge. These were: correct knowledge of the
drug used, time of first dose administration, of second
dose administration, and knowledge of the strategy for
administration (DOT). Emphasis was then laid on de-
scribing deviations from the guidelines with regard to
provider knowledge and behaviour, and the facility-
related factors that may help explain observations. Apart
from description of providers’ behaviour, summary statis-
tics were obtained from the data and presented based on





Knowledge of existence of policy on IPTp 11
Correct knowledge of drug used (SP) 10
Correct knowledge of number of doses (2/3) 8
Know a dose should be given in 2nd trimester 7
Know a dose should be given in 3rd trimester 4
Knowledge of recommended approach of giving IPTp (DOT) 8
Respondents that know all the guidelines 2and whether they were private or public providers. Sum-
mary statistics were also obtained from the facility check-
lists and categorized based on the above characteristics
and the data generated were related to data from the
qualitative data analysis to enhance the understanding and
interpretation of the study findings. The information
obtained from the study was further confirmed by partici-
pants that attended a results dissemination workshop
organized at the end of the study for the health care provi-
ders, as well as state Ministry of Health officials and non-
governmental organizations involved in malaria control in
the state.
Ethical concerns
Approval for this study was obtained from the Research
Ethics Committee of the University of Nigeria Teaching
Hospital Enugu and the London School of Hygiene and
Tropical Medicine. The primary health care (PHC) coor-
dinators for the LGAs used and the heads of primary
health facilities and private hospitals gave permission for
the use of facilities. Written and signed consent forms
were obtained from all individuals interviewed.
Results
Provider knowledge of IPTp policy and guidelines for
delivery
Almost all providers interviewed (94.1%) knew about the
existence of the national policy on IPTp (Table 1). The
Table shows that of all 34 providers interviewed, most
knew the correct drug for IPTp and knew that women
should receive two or three doses. However, few provi-
ders knew the drug should be received in the second
and third trimesters and very few knew it should be
delivered under direct observation by a health worker.
Only five (14.7%) of all the providers satisfied the four
criteria for assessment of knowledge of the IPTp guide-
lines. None of them was a private provider.
Although most respondents knew the correct number
of doses that should be given, the description of whennancy
Rural Total
Private Public Private
1 N = 3 N = 17 N = N = 34
n n n n(%)
2 16 3 32 (94.1)
3 16 3 32 (94.1)
1 14 3 26 (76.5)
2 13 2 24 (70.6)
2 7 0 13 (38.2)
1 7 1 17 (50.0)
0 3 0 5
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four private providers with correct knowledge of number
of doses, one stated that the first dose is “given soon after
quickening (16 weeks) while the second is given one
month after”. Another indicated that two doses are
given, as long as they are given before 36 weeks. How-
ever, they all reported that drugs are not given after
36 weeks of pregnancy.
Amongst the public providers that knew the correct
number of doses, knowledge of timing of administration
varied. According to one provider,“first dose is given after
18 weeks, then second dose is a month after” (urban pro-
vider). For another, the “first dose is given during first tri-
mester, the second during second trimester, and before
36 weeks you give the third dose” (urban provider). An-
other provider (rural area) also stated that “the first is
given after four months of pregnancy and the second, a
month later”. Only two providers (one rural and one
urban) added that a third dose is given if a patient is
HIV positive. Additionally, one provider (rural) stated
that three doses are given to HIV-positive women, but
the dosage depends on her weight: “Those above 50 kg
take three tabs and those below take two tablets” (rural
public provider). However, she stated that the first and
second doses were given in the first and second trime-
sters, respectively, for patients who present early, while
those who present in the second trimester are given one
dose in each of the second and third trimester. All the
public providers reported that IPTp is not given within
the last month of pregnancy.
The six public providers who had incorrect knowledge
of the number of doses indicated that they provided
IPTp to patients monthly. For these providers, the most
common approach was to give the first dose any time
after quickening and then subsequent doses “monthly
until delivery”. None of the providers from the urban
area indicated that a dose should be given in the first tri-
mester while three providers from the rural area (all
CHEWs) stated that it should.
As shown in Table 1, just half of the providers knew
the correct strategy for delivery of IPTp (DOT). This
figure includes providers who stated that the woman
could be given the drug free or could purchase it.
Twelve of the remaining 17 providers stated that the
recommended approach is for the women to take the
drugs home after being given the drug free of charge.
One of the respondents (rural public provider) put it
thus: “a woman is given the drug free in the facility but
she takes it home”.
Provision of IPTp in health facilities
Although about 85% of all providers reported that IPTp
is provided at their facilities, the way this is done dif-
fered. According to a private provider (rural), “we givethe first dose in the first trimester, the second in the sec-
ond trimester. Then we give ACT once”. Among the pub-
lic facility providers in the urban area, the deviations
included that women registered at their various facilities
were given “two tablets stat and one tab(let) the next
day”, “two tablets stat at 20 weeks, then one the following
day at night with routine drugs and paracetamol”,while
another gives “two tablets at five months and three at
seven months when the woman is heavier”. Similar find-
ings were also noted from providers in public facilities in
rural areas. Women were asked to take “two tablets at
night and one tablet in the morning; but if she has mal-
aria, she takes three tablets stat”; “three at once for
women over 60 kg and two at once for those less than
60 kg”; “two tablets stat and one the next day”; and “first
trimester first dose, second dose one month after; if the
woman presents at second trimester, we give first dose
and second dose a month after”. In one facility, clients are
given “one tablet daily for three days to avoid reaction”.
Practice of directly observed treatment
Only one out of six private providers reported practicing
DOT while six of the public did same (Table 2). How-
ever, for 64.7% of all providers, the woman is given the
drug, which she takes home. Women receive SP free in
public facilities, while those in the private facilities are
billed for the drug.
The major reason for the poor practice of DOT
amongst public providers from both rural and urban
areas was that most women complained of not eating
before coming to the facility, and because they and the
health workers considered it unsafe to take drugs on
empty stomachs, they were allowed to take the drugs
home. A key reason given by a health worker why
women came to the hospital without eating was that “for
better palpation, women are not allowed to eat before
coming. This is part of our directive (i e, what health
workers in the facility are directed to do) and since it is
risky to give drugs on empty stomach, they take it at
home after eating” (public provider – rural area). Two
private facility providers saw no reason to place such an
oversight on women, they believed that women knew
enough of the complications of malaria and so do not
have a problem with taking drugs at home. For another
public provider, DOT is not practiced because “it is not
the policy of the hospital for patients to take their medi-
cation in the hospital”. Another private provider believed
that SP is “a routine drug and is given to women along
with other routine drugs” and this is done without seek-
ing the consent of the women or letting her know. An-
other private provider echoed this stating that the drug
is “given to the woman without (her) being told”.
Most of the public facilities (both urban and rural)
reported not having water with which to give the drug
Table 2 Factors related to provision of IPTp in health facilities
Variable Urban Rural Total (%)
Public Private Public Private
11 3 17 3 34
How IPTp is delivered
IPTp is offered in the facility 10 2 15 2 29 (85.3)
DOT is practiced in the facility 3 1 3 0 7 (20.6)
Woman is given drug to take home 7 1 12 2 22 (64.7)
Where drug used for IPTp is sourced
Free from Ministry of Health 10 0 15 0 25 (73.5)
Purchased 0 2 0 2 4 (11.7)
Facility occasionally has periods of drug stock-out 6 1 4 1 12 (35.3)
Source of drugs during stock-out
Direct acquisition from market for sale 1 1 1 1 4 (11.8)
Woman is given prescription to purchase on her own 5 0 3 0 8 (23.5)
Facilities with drugs on day of interview
SP 11 3 15 3 32 (94.1)
ACT 8 3 16 3 30 (88.2)
Quinine 7 1 5 3 16 (47.1)
Complaints about the drug
Side effect 1 2 2 1 6 (17.6)
Irregularity of drug availability 0 0 2 0 2 (5.9)
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ways of overcoming this problem. Women had to buy
“sachet water” if they were to take any medication in the
facility (Sachet water is water provided in 500 ml cap-
acity polybags. Most products have provisional approval
by the National Agency for Food Administration and
Control (NAFDAC). They are cheap ($0.06) and widely
available). Some of the public providers also reported
that some women used rainwater or borehole water
which were free. Three private providers got water from
the state-owned water cooperation but the supply was
reported to be erratic. There was water for delivery of
IPTp in all but one private hospital while 11 out of the
28 public facilities had water. The available water was
pipe-borne in two private facilities, and sachet water in
the remaining facilities that had water. Overall, only two
providers (both public facilities) felt that water was a
concern with regard to IPTp delivery.
Source, availability of, and concerns about sulphadoxine-
pyrimethamine
Public facilities obtained SP supplies free from the state
Ministry of Health while the private ones purchased
drugs from private suppliers. Twelve public facilities oc-
casionally (but infrequently) had drug stock-outs and
used alternative options for obtaining drugs at such
times. For instance, four public facilities obtained drugsfrom private suppliers including patent medicine dealers.
They had difficulties getting drugs from the district store
since they “have to source for transport to go and get the
drugs at Udi (local government health department)”
(provider - rural public facility). On the other hand,
though stock-outs were uncommon amongst private
providers, most of the private providers reported not
waiting until they run out of drugs to make further pur-
chases from the market, in order to avoid interruptions
to service delivery, since women had already been billed
for ANC in advance. The remaining public facilities and
some private providers hand out prescriptions, which
women then fill at private outlets and take at home. SP
was, however, in stock in all but two facilities (both rural
public facilities) on the day of interview. All the provi-
ders reported that women generally do not complain of
the cost of obtaining SP, and do not seem to be worried
about any effect it may have on their babies. Three pub-
lic and three private providers reported that a few
women complained of side effects but this was very in-
frequent and did not hinder them from taking SP. One
added that “the three SP tablets should be made into
one”, to encourage women to use the drug.
Availability of staff for delivery of IPTp
Although all private facilities had at least one skilled birth
attendant, two out of 11 public facilities in the urban area
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area, most facilities saw at most 10 ANC clients/skilled
birth attendant on a given ANC day (Table 3).
The public facility with a client/skilled birth attendant
ratio above 20 actually saw 847 women the preceding
week, giving an average of 85 ANC clients per skilled
birth attendant per day. They had no unskilled staff to
support their activities. One private facility in the urban
area saw 21 clients/skilled birth attendant per day and
had four unskilled staff (auxiliaries) for support services.
All the public facilities in the rural area with skilled birth
attendants saw at most 10 clients/skilled birth attendant
per day. One private facility in the rural area saw 24 cli-
ents/skilled birth attendant per day. This facility had six
auxiliary staff for support activities. All the facilities
without a skilled birth attendant saw at most five
women. The staff were mostly CHEWs. With the excep-
tion of the provider in the public facility that had the
high client/staff ratio noted above, providers at the
results dissemination workshop did not think the avail-
ability of personnel affects the quality of delivery of
ANC services, such as IPTp. Rather, personnel availability
was believed to be more important when women were in
labour. There was, however, a consensus opinion amongst
participants that supervision for ANC activities from se-
nior health officials from within and outside the facility
was quite infrequent, and focused mainly on cross-
checking facility registers for the number of women en-
rolled for antenatal care, and the number and outcome of
deliveries, but not on the content and process of delivery
of most ANC interventions including IPTp.
Discussion
The finding of this study presents an important insight
into existing poor implementation practices affecting
IPTp delivery. While most providers were aware of the
existence of a national policy on IPTp, their overall
knowledge of the guidelines for implementation of the
policy was poor. This was more obvious with the know-
ledge of time of administration of second dose of SP andTable 3 Staff availability for antenatal care
Variable
At least one skilled attendant available
No skilled attendant




ANC client/unskilled attendant per day in facility without skilled personnel: 0the use of DOT strategy for IPTp delivery. The overall
poor knowledge amongst providers found in this study
may have negatively contributed to the low IPTp cover-
age level of 13.7% and 7.3% for first and second doses,
respectively, found for the study area in a related study
[6].
The effectiveness of IPTp intervention, which is com-
promised by the low coverage levels of IPTp in the
Nigeria, is further worsened by poor delivery practices
for the few women that receive SP. The poor knowledge
of guidelines amongst providers was reflected in the
poor delivery practices reported amongst providers,
whether they were categorized as public/private or
across urban/rural. Inappropriate practices such as ask-
ing women to take two tablets on the first day, and the
third the next day, adjusting the number of tablets to
two for women below 50 kg and providing women with
SP monthly, have no clinical basis, can compromise ef-
fectiveness of SP, and may enhance the development of
parasite resistance to SP. The inappropriate adjustment
of the number of tablets also means that such women
received sub-optimal levels of SP required for the
intended protection against malaria. Additionally, the
provision of ANC services in some facilities by unskilled
staff further raised the likelihood of poor IPTp delivery
practices in such facilities.
The practice of DOT is also very poor amongst various
categories of providers, and the reasons for such prac-
tices raises critical concerns with respect to the effective-
ness of IPTp policy. The requirement for women to
attend on empty stomach for the purpose of palpation
seems to have been institutionalized within some facil-
ities, even though the practice has no scientific basis. A
study in Malawi reported that ANC providers felt
women should not take drugs on an empty stomach
[12]. This is similar to the finding that having come with
an empty stomach, women were allowed to take drugs
home. The underlying faulty perception among these
providers needs to be addressed to enhance the practice
of DOT.URBAN RURAL TOTAL
Public Private Public Private 34
11 3 17 3
9 3 10 3 25 (73.5)
2 0 7 0 9 (26.5)
8 1 10 1 20
0 1 0 1 2
1 1 0 1 3
-5 2 0 7 0 9 (26.5)
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correct knowledge did not include a private provider. A
study in south-west Nigeria also found poorer know-
ledge of the guidelines amongst private providers com-
pared to their public sector counterparts, although the
respondents were not restricted to those providing ante-
natal care [14]. Other faulty institutional policies noted
among private providers, such as not allowing women to
take drugs in the facility, and the assumption that
women would take drugs given to them at home, consti-
tute additional impediments to IPTp effectiveness. These
findings highlight the importance of observing the
knowledge and practices of private providers, and ensur-
ing that they comply with national guidelines.
This study could not verify whether women actually
took the drugs that they took home. Nonetheless, obser-
vations elsewhere have reported that women may throw
such drugs away [19]. Allowing women to take drugs
home overrules the very objective of the recommended
DOT strategy. Again, not informing women about the
drugs they are being given, for whatever reason, conflicts
with existing policies for drug administration and safety
[20]. It also means that a woman would be unable to re-
port if she had received SP from a provider, and may re-
ceive multiple doses if registered with more than one
provider.
Unlike the case elsewhere [9,19,21-23], health facility
factors such as availability of water and SP in the facility
do not seem to be important constraining factors to de-
livery of IPTp in this setting. Cheap alternative water
sources existed, SP stock-outs were uncommon and both
providers and the women had insignificant concerns
about side effects.
The results of this study therefore support suggestions
that provider factors rather than demand-side factors,
such as timely attendance to ANC, constrain IPTp deliv-
ery in the study area [6].The findings also suggest that
interventions targeting improvement in provider know-
ledge and behaviour, coupled with supportive supervi-
sion, should result in improved IPTp delivery. Further
research focusing on measuring the effectiveness of pro-
vider training and supervision with respect to IPTp de-
livery is required. In addition, it would be necessary to
understand policy-maker and programme-manager be-
haviour at both state and LGA levels which create the
lapse in monitoring implementation of the policy. There
is also the need to conduct empirical research using the
interpretive policy analysis approach to better diagnose
reasons for gaps in the implementation of national IPTp
guidelines.
Finally, this paper shows that it is just not enough to
have an IPTp policy in place, and attention needs to be
paid to how providers implement policy if intended policy
objectives of reduction in impact of malaria on pregnantwomen and their babies are to be achieved. Low coverage
of IPTp and use of DOT strategy for its administration is
influenced by inappropriate implementation resulting
from poor provider knowledge and practices. Policy
makers and programme managers of malaria control
interventions need to pay attention to monitoring the
IPTp provision system in both urban and rural areas as
well as amongst public and private providers. Efforts at
improving provider practices for IPTp delivery need to go
beyond training them, to setting up effective supervisory
activities aimed at observing their practices and correcting
deviations from recommended policy guidelines. A moni-
toring system should also be in place to periodically assess
the content of antenatal care services being provided by
primary providers.
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